Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 7/20 | 0.50 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA9 | Q16790 | 7/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21106180 | 0.89 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL21534023 | 0.89 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL25985788 | 0.89 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL15691138 | 0.89 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL5675016 | 0.89 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL25985952 | 0.89 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL13699507 | 0.89 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL13526277 | 0.88 | TDP1 (0.62) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL31312814 | 0.87 | TDP1 (0.45) | TDP1MEN1GAAKMT2ACA12 | |
| SCHEMBL1950985 | 0.87 | TDP1 (0.45) | TDP1MEN1GAAKMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113999125-B | Preparation method of 2-methoxyethylamine | 苏州昊帆生物股份有限公司 | 2024-03-05 | — | — | CN | claimed |
| CN-111295386-B | Thienopyridine derivatives and pharmaceutical compositions containing the same | 伟迈可生物有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-113999125-A | Preparation method of 2-methyl ethylamine | 苏州昊帆生物股份有限公司 | 2022-02-01 | — | — | CN | claimed |
| CN-112300012-A | Method for preparing 2-methoxy ethylamine hydrochloride | 上海睿瓦科技有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-113993872-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117813302-A | Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-113999125-B | Preparation method of 2-methoxyethylamine | 苏州昊帆生物股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-113999125-B | Preparation method of 2-methoxyethylamine | 苏州昊帆生物股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| WO-2024044327-A1 | DHNT MONOMERS AND POLYMER DYES WITH MODIFIED PHOTOPHYSICAL PROPERTIES | BECKMAN COULTER, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-116997547-A | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2023-11-03 | — | — | CN | disclosed |
| US-6897305-B2 | Calcium channel drugs and uses | THERAVANCE, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| CN-1568185-A | Compounds affecting glucokinase | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | CN | disclosed |
| US-20040242561-A1 | Novel calcium channel drugs and uses | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-02 | — | — | US | disclosed |
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-04-17 | — | — | US | disclosed |
| WO-1999063992-A9 | NOVEL CALCIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE INC (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1085863-A1 | CROSS-REFERENCE TO RELATED APPLICATIONS | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1085863-A4 | CROSS-REFERENCE TO RELATED APPLICATIONS | ADVANCED MEDICINE INC (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999063992-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | CACNB2, CACNA1B, CACNA1F | TDP1 3946/4885MEN1 3664/4885GAA 2662/4885 |
| US-20040242561-A1 | Novel calcium channel drugs and uses | CACNB2, CACNA1B, CACNA1F | TDP1 3946/4885MEN1 3664/4885GAA 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.